Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Resistance and Sensitivity to Therapy

P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy

Leukemia volume 14, pages 1018–1024 (2000)Cite this article

Abstract

The expression of the drug transport protein, P-glycoprotein (Pgp/MDR1) has been found to be of prognostic significance for the achievement of complete remission (CR) or the duration of survival after daunorubicin (DNR)-containing induction therapy in acute myeloid leukemia (AML). This would suggest that the expression of Pgp in AML is high enough to have significant impact on intracellular DNR concentrations and on clinical therapy failure in AML. Recently, DNR has been replaced in many centers by idarubicin (IDA) as the first choice anthracycline in AML treatment. We have, therefore, performed a study in a group of 98 primary AML patients, who all received IDA, but not DNR during induction therapy in order to determine if the response to IDA-containing induction therapy might be related to the biologic characteristic of Pgp expression in AML. The AML samples were studied for Pgp expression by MRK16 antibody staining and for Pgp activity measured as the modulation of rhodamine 123 uptake by 2 μM PSC 833. No correlation of Pgp with complete response rate, event-free survival or overall survival was found. In addition to Pgp, the expression of another protein that has been implicated by some studies in response failure to DNR-containing therapy, the major vault protein (Mvp/LRP), was studied. This marker did not correlate with CR or survival after IDA-containing therapy. The results of this patient study are consistent with model studies showing that the steady-state cellular accumulation of lipophilic anthracyclines such as IDA are little affected by Pgp. Therefore, putative beneficial effects of the inclusion of PSC 833 in IDA-containing therapy might rather be related to alternative mechanisms than to inhibition of Pgp-mediated IDA efflux.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Bradley G, Juranka PF, Ling V . Mechanisms of multidrug resistance Biochem Biophys Acta 1988 948: 87–128

    CAS  PubMed  Google Scholar 

  2. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D . Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A Int J Cancer 1990 45: 263–268

    Article  CAS  Google Scholar 

  3. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, Ezaki K, Hirano M . Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome Leukemia 1994 8: 1492–1497

    CAS  PubMed  Google Scholar 

  4. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M . Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia Cytometry 1994 17: 84–93

    Article  CAS  Google Scholar 

  5. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherer R, Valent P, Havelec L, Ludwig H, Lechner K . mdr1 gene expression and treatment outcome in acute myeloid leukemia J Natl Cancer Inst 1991 83: 708–712

    Article  CAS  Google Scholar 

  6. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D . Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells Blood 1992 79: 473–476

    CAS  PubMed  Google Scholar 

  7. Willman CL . The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the southwest oncology group leukemia research program Semin Hematol 1997 34: (Suppl.5) 25–33

    CAS  PubMed  Google Scholar 

  8. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 1997 89: 3323–3329

    CAS  PubMed  Google Scholar 

  9. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Währer DCR, Ossenkoppele GJ, Schuurhuis GJ . Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia Leukemia 1997 11: 1110–1118

    Article  CAS  Google Scholar 

  10. Broxterman HJ, Sonneveld P, Pieters R, Lankelma J, Eekman CA, Loonen AH, Schoester M, Ossenkoppele GJ, Löwenberg B, Pinedo HM, Schuurhuis GJ . Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia 1999 13: 258–265

    Article  CAS  Google Scholar 

  11. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, Schuurhuis GJ . Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity Blood 1996 87: 4809–4816

    CAS  PubMed  Google Scholar 

  12. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W . Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia J Clin Oncol 1993 11: 1652–1660

    Article  CAS  Google Scholar 

  13. Sikic BI . Pharmacologic approaches to reversing multidrug resistance Semin Hematol 1997 34: (Suppl.5) 40–47

    CAS  PubMed  Google Scholar 

  14. Coley HM, Twentyman PR, Workman P . Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A Biochem Pharmacol 1998 38: 4467–4475

    Article  Google Scholar 

  15. Consoli U, Priebe W, Ling Y-H, Mahadevia R, Griffin M, Zhao S, Perez-Soler R, Andreeff M . The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines Blood 1996 88: 633–644

    CAS  PubMed  Google Scholar 

  16. Berman E, McBride M . Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells Blood 1992 79: 3267–3273

    CAS  PubMed  Google Scholar 

  17. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, Garnier-Suillerot A . Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells Mol Pharmacol 1996 49: 532–539

    CAS  PubMed  Google Scholar 

  18. Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A . Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells Mol Pharmacol 1998 53: 141–147

    Article  CAS  Google Scholar 

  19. Reiffers J, Huguet F, Stoppa A-M, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P . A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75 Leukemia 1996 10: 389–395

    CAS  PubMed  Google Scholar 

  20. Berman E, Wiernik P, Vogler R, Vélez-Gárcia E, Bartolucci A, Whaley FS . Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with acute myeloid leukemia Cancer 1997 80: 2181–2185

    Article  CAS  Google Scholar 

  21. Müller MR, Lennartz K, Boogen C, Nowrousian MR, Rajewski MF, Seeber S . Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression Ann Hematol 1992 65: 206–212

    Article  Google Scholar 

  22. Michieli M, Damiani D, Michelutti A, Candoni A, Masolini P, Scaggiante B, Quadrifoglio F, Baccarani M . Restoring uptake and retention of daunorubicin and idarubicin in P-170 related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833 Haematologica 1994 79: 500–507

    CAS  PubMed  Google Scholar 

  23. Ross DD, Doyle LA, Yang W, Tong Y, Cornblatt B . Susceptibility of idarubicin, daunorubicin, and their alcohol metabolites to transport-mediated multidrug resistance Biochem Pharmacol 1995 50: 1673–1683

    Article  CAS  Google Scholar 

  24. Sandor V, Fojo T, Bates SE . Future perspectives for the development of P-glycoprotein modulators Drug Resist Updates 1998 1: 190–200

    Article  CAS  Google Scholar 

  25. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS . Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells Cancer Res 1994 54: 4676–4679

    CAS  PubMed  Google Scholar 

  26. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R . MRP expression in acute myeloid leukemia. An update Adv Exp Med Biol 1999 457: 141–150

    Article  CAS  Google Scholar 

  27. Legrand O, Simonin G, Perrot J-Y, Zittoun R, Marie J-P . Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients Blood 1998 91: 4480–4488

    CAS  PubMed  Google Scholar 

  28. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS . Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia Blood 1996 87: 2464–2469

    CAS  PubMed  Google Scholar 

  29. Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL, Lankelma J, Pinedo HM . Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin J Cell Pharmacol 1990 1: 35–41

    CAS  Google Scholar 

  30. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM, Pinedo HM . Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance Cancer Res 1993 53: 1475–1479

    CAS  PubMed  Google Scholar 

  31. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH . Vaults are upregulated in multidrug-resistant cancer cell lines J Biol Chem 1998 273: 8971–8974

    Article  CAS  Google Scholar 

  32. Kickhoefer VA, Vasu SK, Rome LH . Vaults are the answer, what is the question? Trends Cell Biol 1996 6: 174–178

    Article  CAS  Google Scholar 

  33. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geisler K, Lechner K, Pirker R . Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia Blood 1998 91: 1508–1513

    CAS  PubMed  Google Scholar 

  34. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA . Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced survival Br J Haematol 1998 103: 1083–1091

    Article  CAS  Google Scholar 

  35. Leith CP, Kopecky KJ, Chen I-M, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia. A Southwest Oncology Group Study Blood 1999 94: 1086–1099

    CAS  PubMed  Google Scholar 

  36. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper RJ, Baccarini M . P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications Br J Haematol 1999 104: 328–335

    Article  CAS  Google Scholar 

  37. Legrand O, Simonin G, Zittoun R, Marie JP . Lung resistance protein (LRP) gene expression in adult acute leukemia: a critical evaluation by three techniques Leukemia 1998 12: 1367–1374

    Article  CAS  Google Scholar 

  38. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL . Treatment of refractory and relapsed acute myelogenous leukemia with combination therapy plus the multidrug resistance modulator PSC 833 (Valspodar) Blood 1999 93: 787–795

    CAS  PubMed  Google Scholar 

  39. Cabot MC, Han T-Y, Giuliano AE . The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation FEBS Lett 1998 431: 185–188

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Dutch Cancer Society (KWF-VU-93–626) and the VSB-bank.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    HJ Broxterman, J Lankelma, CA Eekman & HM Pinedo

  2. Department of Haematology, University Hospital Dijkzigt, Rotterdam, The Netherlands

    P Sonneveld, GJ Ossenkoppele & B Löwenberg

  3. Department of Statistics, Daniel den Hoed Cancer Center, The Netherlands

    WJL van Putten

  4. Department of Haematology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    GJ Schuurhuis

Authors
  1. HJ Broxterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Sonneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. WJL van Putten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Lankelma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. CA Eekman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. GJ Ossenkoppele
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. HM Pinedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Löwenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. GJ Schuurhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Broxterman, H., Sonneveld, P., van Putten, W. et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 14, 1018–1024 (2000). https://doi.org/10.1038/sj.leu.2401796

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401796

Keywords

This article is cited by

Search

Advanced search

Quick links